UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

Flamel Technologies S.A.

(Translation of registrant’s name into English)

Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)

     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ		Form 40-F o

     Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o		No þ

     If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                    

 

 

INFORMATION FILED WITH THIS REPORT

     Document Index

     99.1 Press release regarding 2009 second quarter results, dated August 5, 2009.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Flamel Technologies S.A.
Dated: August 6, 2009		By:		/s/ Stephen H. Willard
		Name:		Stephen H. Willard
		Title:		Chief Executive Officer

EXHIBIT INDEX

Exhibit
Number		Description
99.1		Press release regarding 2009 second quarter results dated August 5, 2009.

Exhibit 99.1

For Immediate Release

Flamel Technologies Announces Second Quarter 2009 Results; Multiple
New Projects; Cash Increases from $39.1 to $45.1 million

LYON, France—August 5, 2009—Flamel Technologies (Nasdaq:FLML) today announced its financial results for the second quarter of 2009. Highlights in the second quarter included:

	•		the agreement between Flamel and Baxter Pharmaceuticals to develop controlled release formulations of certain blood factors based upon the Medusa® platform, pursuant to which the Company received a €2.5 MM technology access fee;
	•		the signing of two further Medusa projects; and
	•		an increase in the Company’s cash and marketable securities from $39.1 million at the end of the first quarter to $45.1 MM.

Stephen H. Willard, Flamel’s chief executive officer, commented, “Our results this quarter directly derive from work we initiated or continued with partners over the past few quarters. These projects are proceeding well and provide us with a substantial foundation for future growth opportunities. Revenues from projects we have undertaken with Baxter and our other partners in the second quarter will be reflected in our results for the remainder of the year.”

“Flamel is currently working on 19 projects, including those with Merck Serono, Wyeth, and Pfizer, as well as other un-named partners. We are diversified across both new and existing molecules, in a variety of therapeutic areas. We believe we have built a very strong foundation for the growth we expect for the remainder of this year and beyond.”

Flamel reported total revenues in the second quarter 2009 of $9.6 million, compared to $9.2 million in the year-ago period. License and research revenues grew to $4.3 million versus $3.2 million in the second quarter of 2008. Product sales and services totaled $2.5 million during the quarter versus $3.2 million in the second quarter, 2008. Other revenues during the second quarter of 2009, including royalties on the sale of Coreg CR™, were $2.7 million versus $2.8 million in the year-ago period.

Costs and expenses during the second quarter of 2009 were $(14.8) million versus $(14.9) million in the year-ago period. Costs of goods and services sold in the quarter totaled $(1.9) million versus $(2.2) million in the second quarter of 2008. Research and development expenses were $(9.6) million versus $(9.0) million in the second quarter of 2008. SG&A declined to $(3.3) million from $(3.7) million in the year-ago period.

Net loss in the second quarter of 2009 was $(3.6) million, compared to a net loss of $(3.4) million in the second quarter of 2008. Net loss per share (basic) for the second quarter of 2009 was ($0.15), compared to a net loss per share (basic) in the year-ago period of ($0.14).

Cash and marketable securities at the end of the second quarter totaled $45.1 million versus $39.1 million at the end of the first quarter, 2009. This marked the third consecutive quarter that the Company increased its cash and marketable securities position.

For the first half of 2009, Flamel reported total revenues of $21.6 million versus $20.0 million in the first half of 2008. License and research revenues during the period were $11.4 million versus $6.7 million in the year-ago period. Product sales and services during the first six months of 2009 were $5.0 million versus $7.9 million in the first half of 2008. Other revenues during the first six months of 2009 were $5.3 million versus $5.4 million in the year-ago period.

During the first six months of 2009, total costs and expenses declined to $(27.2) million, from $(30.6) million in the year-ago period. Costs of goods and services sold in the first half of 2009 totaled $(3.9) million versus $(4.7) million in the year-ago period. Research and development expenses during the first half of 2009 were $(17.0) million versus $(18.2) million during the year-ago period. SG&A for the first six months of 2009 amounted to $(6.2) million versus $(7.8) million in the year-ago period.

Net loss in the first half of 2009 was $(2.4) million, compared to a net loss of $(7.1) million in the first half of last year. Net loss per share (basic) for the first half of 2009 was $(0.10), compared to net loss per share (basic) in the year-ago period of $(0.29).

A conference call to discuss earnings is scheduled for 8:30 AM EDT August 6, 2009. The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 432624. International investors are invited to dial 1 412-858-4600.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump^® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel’s Medusa^® technology is designed to deliver controlled-release formulations of proteins, peptides, as well as other large and small molecules.

Charles Marlio, Director of Strategic Planning and Investor Relations

Tel:       + (33) (0)4-7278-3434

Fax:       + (33) (0)4-7278-3435

Marlio@flamel.com

This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel’s reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel’s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2008.

Schedule attached

Financial Statements (Unaudited)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)
(Amounts in thousands of dollars except share data)

		Three months ended June 30,								Six months ended June 30,
		2008				2009				2008				2009
Revenue:
License and research revenue		$	3,157			$	4,341			$	6,701			$	11,430
Product sales and services			3,173				2,529				7,895				4,951
Other revenues			2,823				2,705				5,422				5,248
Total revenue			9,153				9,575				20,018				21,629
Costs and expenses:
Cost of goods and services sold			(2,241	)			(1,891	)			(4,650	)			(3,941	)
Research and development			(8,960	)			(9,598	)			(18,237	)			(16,983	)
Selling, general and administrative			(3,686	)			(3,287	)			(7,760	)			(6,233	)
Total			(14,887	)			(14,776	)			(30,647	)			(27,157	)
Profit (loss) from operations			(5,734	)			(5,201	)			(10,629	)			(5,528	)
Interest income net			369				139				750				257
Foreign exchange gain (loss)			(31	)			(74	)			(144	)			(148	)
Other income (loss)			70				2				101				9
Income (loss) before income taxes			(5,326	)			(5,134	)			(9,922	)			(5,410	)
Income tax benefit (expense)			1,968				1,584				2,868				3,050
Net income (loss)		$	(3,358	)		$	(3,550	)		$	(7,054	)		$	(2,360	)
Earnings (loss) per share
Basic earnings (loss) per ordinary share		$	(0.14	)		$	(0.15	)		$	(0.29	)		$	(0.10	)
Diluted earnings (loss) per share		$	(0.14	)		$	(0.15	)		$	(0.29	)		$	(0.10	)
Weighted average number of shares outstanding (in thousands) :
Basic			24,067				24,220				24,061				24,213
Diluted			24,067				24,220				24,061				24,213